News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.